331258-40-3

Upstream product

• 20989-42-8 N-benzoylserine methyl ester 
• 38053-91-7 2-trimethylsilyloxy-1,3-butadiene 
• 24153-31-9 2-benzoylaminoacrylic acid methyl ester 
• 10144-46-4 N-benzoyl-L-serine methyl ester 
• 887245-67-2 methyl 1-amino-4-oxocyclohexanecarboxylate 
• 98-88-4 benzoyl chloride 
• 1239450-42-0 2-benzoylamino-3-methoxy-3-oxo-propanol benzoate 
• 331258-39-0 methyl 1-benzimido-4-oxo-2-cyclohexene-1-carboxylate 
• 4507-57-7 methyl 1-aminocyclohexanecarboxylate 
• 2756-85-6 1-aminocyclohexane carboxylic acid 

Downstream Products

• 331258-41-4 methyl 1-benzimido-c-4-methanesulfonyloxycyclohexane-r-1-carboxylate 
• 936545-59-4 methyl 1-(benzamido)-4-methylenecyclohexanecarboxylate 
• 182137-60-6 7-[(benzyloxy)carbonyl]-7-azabicyclo[2.2.1]heptane-1-carboxylic acid 
• 182137-63-9 benzyl 1-(chlorocarbonyl)-7-azabicyclo[2.2.1]heptane-7-carboxylate 
• 1330783-90-8 benzyl 1-(6-bromo-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidin-2-yl)-7-azabicyclo[2.2.1]heptane-7-carboxylate 
• 1330783-91-9 benzyl 1-{6-[1-(tert-butoxycarbonyl)-3-methyl-1H-pyrazol-4-yl]-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidin-2-yl}-7-azabicyclo[2.2.1]heptane-7-carboxylate 
• 331258-42-5 methyl N-benzoyl-7-azabicyclo[2.2.1]heptane-1-carboxylate 
• 936545-65-2 1-hydroxymethyl-2-azabicyclo[2.2.2]octane 
• 936545-61-8 C₁₇H₂₃NO₆S 
• 936545-60-7 C₁₆H₂₁NO₄ 

Relevant academic research and scientific papers

Bruton's tyrosine kinase inhibitor

The invention relates to a compound with a formula I and a pharmaceutically acceptable salt, a solvent compound, an active metabolite, a polycrystalline compound, an ester, an isomer or a prodrug thereof, a pharmaceutical composition containing the compound in the formula I, and application using the same as a selective Bruton's tyrosine kinase inhibitor to prepare a medicine for preventing or treating heterologous immunity diseases and self immunity diseases or cancers. The formula is shown in the specification.

Scalable, Electrochemical Oxidation of Unactivated C-H Bonds

A practical electrochemical oxidation of unactivated C-H bonds is presented. This reaction utilizes a simple redox mediator, quinuclidine, with inexpensive carbon and nickel electrodes to selectively functionalize "deep-seated" methylene and methine moieties. The process exhibits a broad scope and good functional group compatibility. The scalability, as illustrated by a 50 g scale oxidation of sclareolide, bodes well for immediate and widespread adoption.

HETEROCYCLIC COMPOUND

Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.

Visible-light-triggered release of nitric oxide from N-pyramidal nitrosamines

Although many organic/inorganic compounds that release nitric oxide (NO) upon photoirradiation (phototriggered caged-NOs) have been reported, their photoabsorption wavelengths mostly lie in the UV region, because X - NO bonds (X=heteroatom and metal) generally have rather strong π-bond character. Thus, it is intrinsically difficult to generate organic compounds that release NO under visible light irradiation. Herein, the structures and properties of N-pyramidal nitrosamine derivatives of 7-azabicyclo[2.2.1]heptanes that release NO under visible light irradiation are described. Bathochromic shifts of the absorptions of these nitrosamines, attributed to HOMO (n)-LUMO (π*) transitions associated with the nonplanar structure of the N - NO moiety, enable the molecules to absorb visible light, which results in N - NO bond cleavage. Thus, these compounds are innate organic caged-NOs that are uncaged by visible light. A visible difference: Nitrosamine derivatives of 7-azabicyclo[2.2.1]heptanes undergo N - NO bond cleavage upon exposure to visible light at wavelengths longer than 420a nm, thereby releasing NO. Bathochromic shifts of the absorptions of these nitrosamines are attributed to HOMO (n)-LUMO (π*) transitions associated with the nonplanar structure of the N - NO moiety (see figure). Copyright

Stereoselective Synthesis of Amino Acid Analogs for Tumor Imaging

The radiolabeled non-natural amino acid 1-amino-3-cyclobutane-1-carboxylic acid (ACBC) and its analogs are candidate tumor imaging agents useful for positron emission tomography and single photon emission computed tomography due to their selective affinity for tumor cells. The present invention provides methods for stereo-selective synthesis of syn-ACBC analogs. The disclosed synthetic strategy is reliable and efficient and can be used to synthesize a gram quantity of various syn-isomers of the ACBC analogs, particularly, syn-[18F]-1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC) and syn-[123I]-1-amino-3-iodocyclobutane-1-carboxylic (IACBC) acid analogs.

New synthesis of 7-azabicyclo[2.2.1]heptane-1-carboxylic acid

This report describes a new synthetic route to 7-azabicyclo[2.2.1]heptane-1-carboxylic acid (Ahc), a constrained proline analogue, in which the key step is the Diels-Alder reaction using methyl 2-benzamidoacrylate as dienophile.